Registry study for people with neuroendocrine tumors in Switzerland
Part of Cancer clinical trials.
This study sets up a national registry to collect information about people with neuroendocrine tumors. It helps researchers understand these cancers better and improve care over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a neuroendocrine tumor
- Your diagnosis was in Switzerland
- You are willing to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from patients with neuroendocrine tumors that affect the heart. It aims to better understand and treat this rare condition by gathering data from routine tests and procedures.
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
This trial asks adults with a neuroendocrine tumor to share their study experiences through surveys or interviews. It may help researchers understand what supports or challenges people face during care and research.
This study is creating a registry (a database) to gather information about people with spinal tumors who are undergoing surgery. By joining, you help doctors better understand these tumors and improve future treatments.
This study builds a “registry,” which is a secure list of people with rare diseases or suspected rare diseases in Switzerland. It helps researchers better understand these conditions over time and improve care.
This study is a “registry,” meaning researchers collect health information from people who have surgery for certain hormone-related tumors. It may help doctors better understand outcomes and improve future care for endocrine tumors.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.